LXEO
Lexeo Therapeutics, Inc. Common Stock NASDAQ Listed Nov 3, 2023$5.81
Mkt Cap $430.4M
52w Low $2.43
39.5% of range
52w High $10.99
50d MA $6.26
200d MA $7.09
P/E (TTM)
-3.1x
EV/EBITDA
-49.2x
P/B
12.6x
Debt/Equity
0.0x
ROE
-40.5%
P/FCF
-53.8x
RSI (14)
—
ATR (14)
—
Beta
2.00
50d MA
$6.26
200d MA
$7.09
Avg Volume
927.5K
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
345 PARK AVENUE SOUTH · NEW YORK, NY 10010 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.32 | -0.27 | +15.6% | 5.27 | +11.2% | +8.9% | -1.2% | +0.9% | +0.9% | +9.4% | — |
| Nov 5, 2025 | AMC | -0.48 | -0.33 | +31.2% | 8.20 | +0.4% | +2.7% | -2.7% | +4.0% | +7.0% | +1.0% | — |
| Aug 14, 2025 | AMC | -0.64 | -0.60 | +6.2% | 4.79 | +2.5% | -1.5% | +4.2% | -2.8% | +0.4% | -0.4% | — |
| May 12, 2025 | AMC | -0.80 | -0.99 | -23.8% | 2.63 | +0.4% | +7.6% | -4.9% | +0.4% | +20.0% | +1.5% | — |
| Mar 24, 2025 | AMC | -0.87 | -0.78 | +10.3% | 4.09 | +2.4% | +8.6% | -10.1% | +3.0% | -0.2% | -15.4% | — |
| Nov 13, 2024 | AMC | -0.65 | -0.89 | -36.9% | 7.64 | +0.8% | +1.8% | -14.5% | -9.8% | +0.3% | +1.7% | — |
| Aug 12, 2024 | AMC | -0.69 | -0.64 | +7.2% | 11.98 | -0.8% | -2.3% | -0.1% | +3.5% | +0.9% | -2.6% | — |
| May 9, 2024 | AMC | -0.76 | -0.77 | -1.3% | 14.50 | -0.1% | -9.4% | +3.2% | +3.0% | -0.1% | +0.4% | — |
| Mar 11, 2024 | AMC | -0.73 | -0.85 | -16.4% | 14.49 | +3.0% | +8.3% | +5.7% | -5.4% | -0.7% | +0.9% | — |
| Nov 6, 2023 | AMC | -2.60 | -12.36 | -375.4% | 10.50 | +0.0% | -0.4% | +1.7% | +2.0% | -0.6% | -2.4% | — |
| Jun 30, 2023 | AMC | — | -0.53 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.74 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 13 | Chardan Capital | Maintains | Buy → Buy | — | $8.12 | $8.11 | -0.1% | -8.5% | +3.9% | -2.8% | -1.5% | -1.8% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.12 | $8.11 | -0.1% | -8.5% | +3.9% | -2.8% | -1.5% | -1.8% |
| Dec 11 | Chardan Capital | Maintains | Buy → Buy | — | $9.73 | $9.75 | +0.2% | +0.7% | -0.3% | -0.1% | -0.3% | -6.4% |
| Nov 5 | Chardan Capital | Maintains | Buy → Buy | — | $8.35 | $8.27 | -1.0% | -1.8% | +2.7% | -2.7% | +4.0% | +7.0% |
| Oct 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.22 | $9.23 | +0.1% | +4.1% | -3.9% | -2.5% | +2.6% | +6.6% |
| Oct 7 | Leerink Partners | Maintains | Outperform → Outperform | — | $6.47 | $8.25 | +27.5% | +28.9% | -3.7% | +2.1% | +0.5% | -0.5% |
| Oct 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.47 | $8.25 | +27.5% | +28.9% | -3.7% | +2.1% | +0.5% | -0.5% |
| Oct 7 | Chardan Capital | Maintains | Buy → Buy | — | $6.47 | $8.25 | +27.5% | +28.9% | -3.7% | +2.1% | +0.5% | -0.5% |
| Aug 15 | Chardan Capital | Maintains | Buy → Buy | — | $4.79 | $4.91 | +2.5% | -1.5% | +4.2% | -2.8% | +0.4% | -0.4% |
| Aug 15 | Leerink Partners | Maintains | Outperform → Outperform | — | $4.79 | $4.91 | +2.5% | -1.5% | +4.2% | -2.8% | +0.4% | -0.4% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.79 | $4.91 | +2.5% | -1.5% | +4.2% | -2.8% | +0.4% | -0.4% |
| May 30 | JP Morgan | Maintains | Overweight → Overweight | — | $2.87 | $2.87 | +0.0% | -5.2% | +0.0% | +3.7% | +9.9% | +5.5% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.70 | $2.76 | +2.2% | +20.0% | +1.5% | +7.3% | -13.3% | +0.7% |
| May 13 | Chardan Capital | Maintains | Buy → Buy | — | $2.63 | $2.64 | +0.4% | +7.6% | -4.9% | +0.4% | +20.0% | +1.5% |
| May 12 | Leerink Partners | Maintains | Outperform → Outperform | — | $2.69 | $2.79 | +3.7% | -2.2% | +7.6% | -4.9% | +0.4% | +20.0% |
| Apr 8 | Chardan Capital | Maintains | Buy → Buy | — | $1.79 | $1.93 | +7.8% | +1.7% | +29.7% | -8.1% | -8.8% | +8.1% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.79 | $1.93 | +7.8% | +1.7% | +29.7% | -8.1% | -8.8% | +8.1% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.44 | $4.59 | +3.4% | -10.1% | +3.0% | -0.2% | -15.4% | -9.8% |
| Mar 25 | RBC Capital | Maintains | Outperform → Outperform | — | $4.09 | $4.19 | +2.4% | +8.6% | -10.1% | +3.0% | -0.2% | -15.4% |
| Mar 25 | Chardan Capital | Maintains | Buy → Buy | — | $4.09 | $4.19 | +2.4% | +8.6% | -10.1% | +3.0% | -0.2% | -15.4% |
| Mar 24 | Leerink Partners | Maintains | Outperform → Outperform | — | $2.71 | $2.99 | +10.3% | +50.9% | +8.6% | -10.1% | +3.0% | -0.2% |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | $5.07 | $5.15 | +1.6% | -3.7% | +0.4% | +14.5% | -0.5% | +5.2% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.64 | $7.70 | +0.8% | +1.8% | -14.5% | -9.8% | +0.3% | +1.7% |
| Nov 13 | Chardan Capital | Maintains | Buy → Buy | — | $7.69 | $8.65 | +12.5% | -0.7% | +1.8% | -14.5% | -9.8% | +0.3% |
| Nov 13 | Leerink Partners | Maintains | Outperform → Outperform | — | $7.69 | $8.65 | +12.5% | -0.7% | +1.8% | -14.5% | -9.8% | +0.3% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.28 | $8.31 | +0.4% | -4.6% | +0.4% | +3.9% | -2.5% | +2.1% |
| Oct 30 | Chardan Capital | Maintains | Buy → Buy | — | $9.97 | $8.85 | -11.2% | -17.0% | -4.6% | +0.4% | +3.9% | -2.5% |
| Oct 25 | Chardan Capital | Maintains | Buy → Buy | — | $9.90 | $9.91 | +0.1% | -4.0% | +3.5% | +1.4% | -17.0% | -4.6% |
| Aug 14 | Chardan Capital | Maintains | Buy → Buy | — | $11.70 | $11.83 | +1.1% | -0.1% | +3.5% | +0.9% | -2.6% | +2.4% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.98 | $11.88 | -0.8% | -2.3% | -0.1% | +3.5% | +0.9% | -2.6% |
| Aug 13 | RBC Capital | Maintains | Outperform → Outperform | — | $11.98 | $11.88 | -0.8% | -2.3% | -0.1% | +3.5% | +0.9% | -2.6% |
| Jul 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.01 | $13.31 | +2.3% | -2.8% | -10.4% | -2.0% | +0.9% | +3.1% |
| Jul 15 | Chardan Capital | Maintains | Buy → Buy | — | $17.60 | $14.09 | -19.9% | -26.1% | -2.8% | -10.4% | -2.0% | +0.9% |
| Mar 12 | RBC Capital | Maintains | Outperform → Outperform | — | $14.49 | $14.92 | +3.0% | +8.3% | +5.7% | -5.4% | -0.7% | +0.9% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
LXEO filed a material announcement regarding its genetic medicine pipeline for cardiovascular diseases, likely signaling clinical progress or strategic developments that could significantly impact the company's valuation and clinical-stage risk profile.
Mar 30
8-K · 5.02
!!! Very High
Lexeo Therapeutics, Inc. -- 8-K 5.02: Executive Change
Lexeo Therapeutics' director Adler resigned effective February 1, 2026, representing a leadership change that investors should monitor for potential impacts on company governance and strategic direction.
Feb 5
Data updated apr 25, 2026 8:12pm
· Source: massive.com